恩格列净对心力衰竭患者心脏能量代谢、功能及生理的影响:EMPA-VISION随机对照试验
EMPA-VISION是一项前瞻性、随机、双盲、安慰剂对照的机制性试验,纳入72例慢性心衰患者(HFrEF 36例,HFpEF 36例),随机接受恩格列净10 mg每日一次或安慰剂治疗12周。主要终点为心脏磷酸肌酸/ATP比值(PCr/ATP)从基线至第12周的变化,通过磷磁共振波谱在静息和峰值多巴酚丁胺负荷下测定。结果显示,恩格列净未改变HFrEF或HFpEF患者静息或负荷下的心脏能量学,也未改变血清代谢组学或循环酮体水平。
要点
- 恩格列净10 mg每日一次治疗12周未改善HFrEF或HFpEF患者的心脏能量学(PCr/ATP)。
- 恩格列净未改变血清代谢组学或循环酮体水平。
- 增强心脏能量代谢不太可能是SGLT2i在心衰中获益的机制。
核心结论
- 在HFrEF或HFpEF患者中,恩格列净10 mg每日一次治疗12周未改善心脏能量学或改变与能量代谢相关的循环血清代谢物。
- 基于本研究结果,增强心脏能量代谢不太可能介导SGLT2i在心衰中的有益效应。
研究设计与样本
- EMPA-VISION为前瞻性、随机、双盲、安慰剂对照的机制性试验,纳入72例症状性慢性心衰患者。
- HFrEF组36例(LVEF≤40%,NYHA≥II,NT-proBNP≥125 pg/mL),HFpEF组36例(LVEF≥50%,NYHA≥II,NT-proBNP≥125 pg/mL)。
- 患者按HFrEF与HFpEF分层后随机分配至恩格列净10 mg每日一次(n=35:HFrEF 17例,HFpEF 18例)或安慰剂(n=37:HFrEF 19例,HFpEF 18例),治疗12周。
- 主要终点为心脏PCr/ATP从基线至第12周的变化,通过磷磁共振波谱在静息和峰值多巴酚丁胺负荷(年龄最大心率的65%)下测定。
- 对19种目标代谢物在基线和治疗后进行质谱分析。
主要发现
- 恩格列净未改变HFrEF患者静息心脏能量学(PCr/ATP),校正平均治疗差异为-0.25(95%CI -0.58至0.09;P=0.14)。
- 恩格列净未改变HFpEF患者静息心脏能量学,校正平均治疗差异为-0.16(95%CI -0.60至0.29;P=0.47)。
- 恩格列净未改变HFrEF患者多巴酚丁胺负荷下PCr/ATP,校正平均治疗差异为-0.13(95%CI -0.35至0.09;P=0.23)。
- 恩格列净未改变HFpEF患者多巴酚丁胺负荷下PCr/ATP,校正平均治疗差异为-0.22(95%CI -0.66至0.23;P=0.32)。
- 未观察到血清代谢组学或循环酮体水平的变化。
临床怎么用
- 对于HFrEF或HFpEF患者,不应以改善心脏能量代谢作为恩格列净治疗的预期机制。
- 恩格列净的临床获益可能通过能量代谢以外的途径介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness. METHODS: EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated. RESULTS: Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin - placebo], -0.25 [95% CI, -0.58 to 0.09]; P=0.14) or HFpEF (adjusted mean treatment difference, -0.16 [95% CI, -0.60 to 0.29]; P=0.47]. Likewise, there were no changes in PCr/ATP during dobutamine stress in HFrEF (adjusted mean treatment difference, -0.13 [95% CI, -0.35 to 0.09]; P=0.23) or HFpEF (adjusted mean treatment difference, -0.22 [95% CI, -0.66 to 0.23]; P=0.32). No changes in serum metabolomics or levels of circulating ketone bodies were observed. CONCLUSIONS: In patients with either HFrEF or HFpEF, treatment with 10 mg of empagliflozin once daily for 12 weeks did not improve cardiac energetics or change circulating serum metabolites associated with energy metabolism when compared with placebo. Based on our results, it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03332212.
引用
- Hundertmark, Adler, Antoniades, et al. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation. 2023. PMID: 37070436. doi:10.1161/CIRCULATIONAHA.122.062021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。